Gosset Avian influenza virus hemagglutinin protein Overview
The avian influenza virus hemagglutinin protein is a trimeric glycoprotein found on the surface of influenza viruses, acting as the primary protein responsible for viral entry into host cells[1][2][3][4][5]. Hemagglutinin mediates two essential steps: binding to sialic acid–containing receptors on host cells (receptor binding) and triggering the fusion of the viral envelope with the host cell membrane (membrane fusion) in response to the low pH of endosomes[1][3][4][5]. It is synthesized as an inactive precursor (HA0), which is later cleaved into HA1 and HA2 subunits required for fusion competence; avian influenza strains often have specific cleavage sites associated with increased pathogenicity in some hosts[3][5]. HA is the main target of neutralizing antibodies and is the protein most commonly used for influenza vaccine formulation and diagnostic assays due to its immunogenicity and subtype diversity (e.g., H5 in H5N1, H7 in H7N9)[1][4][5]. Its rapid antigenic evolution is a key challenge for durable immune protection and therapeutic targeting.
Mechanism of Action
Inhibition of receptor binding (blocking HA-sialic acid interaction); Inhibition of membrane fusion (blocking conformational rearrangements required for viral entry); Induction of neutralizing antibodies (vaccination-mediated, targets HA head and stalk domains)
Biological Functions
Disease Associations
Safety Considerations
- Antigenic drift and shift—high mutation rate of HA can render vaccines or antibody therapies ineffective season-to-season[5]
- Immune escape due to hypervariability in HA head region[5]
- Limited cross-strain protection by current vaccines
Interacting Drugs
Associated Biomarkers
| Biomarker |
|---|
| Antibody titers against hemagglutinin (used in hemagglutination inhibition assays for influenza immunity/Vaccine efficacy) |
| Subtype-specific HA detection (e.g., H5 or H7 for avian influenza diagnostic tests) |